AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3981950
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UF heparin)
Trial: 2012293
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin
Trial: 25920709
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy (60 Gy over 6 weeks) and temozolomide (75 mg/m(2)), followed by six adjuvant 28‐day cycles of either dose‐dense (150 mg/m(2), days 1‐7, 15‐21) or metronomic (50 mg/m(2), days 1‐28) temozolomide, and maintenance RA (100 mg/m(2), days 1‐21/28) until disease progression.
Trial: 22030896
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (120 mg two times a day)
Trial: 6428290
Drug: L-thyroxine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine therapy
Trial: 31084985
Drug: RIPCmultiple (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIPCmultiple (daily RIPC for 6 days plus RIPC during 40 min before LPS), n=10
Trial: 21907422
Drug: Candesartan 32
RxNorm normalized name: candesartan 32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 32 mg once daily on top of conventional treatment
Trial: 21719107
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus insulin glulisine (glargine/glulisine)
Trial: 21719107
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin analogues
Trial: 18160344
Drug: Intervention (nurse-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (nurse-led lifestyle counselling and preparation for surgery at monthly intervals)
Trial: 16822451
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and a thieno-pyridine
Trial: 14679093
Drug: Insulin (Ins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (Ins group)
Trial: 8688986
Drug: Erdosteine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (300 mg x 2/day) with amoxycillin (1500 mg/day)
Trial: 8688986
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with amoxycillin (1500 mg/day)
Trial: 2244610
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V potassium (40 to 50 mg/kg per day for 10 days)
Trial: 2244610
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate (30 to 40 mg/kg per day for 10 days)
Trial: 2244610
Drug: Cephalexin monohydrate
RxNorm normalized name: Cephalexin Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin monohydrate (40 to 50 mg/kg per day for 10 days)
Trial: 19128368
Drug: Rimonabant followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimonabant followed by Metformin
Trial: 25161160
Drug: Metformin only
RxNorm normalized name: Metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin only
Trial: 7976695
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) - 30 mg weekly for one month, then monthly for one year
Trial: 7976695
Drug: Interferon Alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon Alpha 2B (IFN) - 50 million units weekly for 3 months, then monthly for one year
Trial: 17274828
Drug: CQR-300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQR-300 (300 mg daily)
Trial: 29912570
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn starch, 300 mg daily)
Trial: 28284844
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (target dose: 15-20mg/week)
Trial: 25967706
Drug: Boswellia-based cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia-based cream (Bosexil(R))
Trial: 17685703
Drug: CHO+P gel
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+P gel (0.15 g CHO + 0.038 g protein x kg BW(-1))
Trial: 17685703
Drug: CHO gel
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO gel (0.15 g CHO x kg BW(-1))
Trial: 17685703
Drug: CHO+P gel
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+P gel
Trial: 17685703
Drug: CHO gel
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO gel
Trial: 3339726
Drug: Doxorubicin twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin twice weekly for 6 weeks
Trial: 3339726
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment after transurethral resection
Trial: 30091218
Drug: SAR425899 (0.01-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR425899 (0.01-0.1 mg single ascending doses)
Trial: 30091218
Drug: SAR425899 (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR425899 (daily doses over 21 or 28 days)
Trial: 27736032
Drug: High-dose unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose unfractionated heparin (100 units kg-1 bolus)
Trial: 27736032
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (50 units kg-1 bolus)
Trial: 23839107
Drug: CYD tetravalent
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYD tetravalent dengue vaccine (TDV)
Trial: 21172891
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m² on day 1 of induction course 1 with various induction schedules
Trial: 21172891
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytarabine
Trial: 21172891
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with GO
Trial: 12487322
Drug: Andrographis paniculata
RxNorm normalized name: Andrographis paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andrographis paniculata extract SHA-10 fixed combination, Kan Jang, taken for 5 days
Trial: 9796558
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (250 mg b.d. for 5 days)
Trial: 9796558
Drug: Clarithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (250 mg b.d. for 7 days)
Trial: 8585285
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine using immunopotentiating reconstituted influenza virosomes (IRIV)
Trial: 8585285
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine using IRIV with all five vaccines
Trial: 8585285
Drug: Combined vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vaccine with halved quantity of Di‐Te antigen
Trial: 8585285
Drug: Di‐Te vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Di‐Te vaccination in the combination
Trial: 8585285
Drug: Alum‐adsorbed single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum‐adsorbed single vaccines
Trial: 2495813
Drug: Alinidine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 30 mg alone
Trial: 2495813
Drug: Alinidine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 30 mg + Atenolol 25 mg
Trial: 2495813
Drug: Alinidine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 30 mg + Nifedipine retard 20 mg
Trial: 2495813
Drug: Alinidine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 30 mg + Glyceryl trinitrate 500 micrograms
Trial: 29703990
Drug: Topical pharyngeal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pharyngeal anesthesia with propofol sedation
Trial: 29703990
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (propofol sedation without topical pharyngeal anesthesia)
Trial: 22353786
Drug: Mometasone cream
RxNorm normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone cream (0.1%)
Trial: 22353786
Drug: Mometasone comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone comparator (fatty cream with mometasone furoate 0.1%)
Trial: 16012273
Drug: SSRI antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI antidepressants
Trial: 11239615
Drug: MPA/E(2)C (Lunelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA/E(2)C (Lunelle Monthly Contraceptive Injection)
Trial: 11239615
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral contraceptives
Trial: 8986246
Drug: E.P.D. (Enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E.P.D. (Enzyme Potentiated Desensitization) immunotherapy, administered via intradermal injection at extremely low doses once a year for seasonal allergies and twice a year for non-seasonal allergies
Trial: 1592650
Drug: Adjuvant portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant portal infusion (5‐Fluorouracil, Mitomycin C)
Trial: 6693604
Drug: 0.3% anthralin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% anthralin ointment for 10 minutes daily
Trial: 6693604
Drug: Conventional strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional strength (0.1%-0.5%) anthralin ointment overnight
Trial: 6693604
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration anthralin (0.5%-3%) for short contact periods of 10 minutes daily
Trial: 6693604
Drug: Topical steroid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid, difluorosone diacetate
Trial: 27005817
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele carriers of rs13431554
Trial: 19882176
Drug: Single 150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 150-mg oral dose of casopitant
Trial: 19882176
Drug: 3-day IV/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day IV/oral casopitant
Trial: 19882176
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral casopitant vs Control
Trial: 19882176
Drug: 3-day IV/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day IV/oral casopitant vs Control
Trial: 16889952
Drug: Flixotide Diskus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flixotide Diskus (FP) 500-0 mcg/day
Trial: 16889952
Drug: Pulmicort Turbuhaler
RxNorm normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Turbuhaler (BUD) 800-0 mcg/day
Trial: 16529064
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (rivastigmine)
Trial: 31811128
Drug: No primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No primaquine treatment
Trial: 8557961
Drug: Amiloride+hydrochlorothiazide (2.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride+hydrochlorothiazide (2.5/25 mg once a day)
Trial: 6863363
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional guanethidine
Trial: 6863363
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional reserpine
Trial: 28376877
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine
Trial: 30548977
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol + lorazepam
Trial: 30457119
Drug: Fast motion-including
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast motion-including dose reconstruction for proton pencil beam scanning
Trial: 26924621
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh reinforcement during stoma closure
Trial: 21565149
Drug: Indoor Residual
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoor Residual Spray (IRS)
Trial: 17052140
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication monitoring
Trial: 12737331
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (low-level laser therapy)
Trial: 11059532
Drug: i.v. polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. polyethylene glycol‐treated human immunoglobulin at 200 mg/kg per day
Trial: 11059532
Drug: i.v. polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. polyethylene glycol‐treated human immunoglobulin at 400 mg/kg per day
Trial: 11059532
Drug: freeze‐dried sulfonated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: freeze‐dried sulfonated human immunoglobulin at 200 mg/kg per day
Trial: 9080749
Drug: Resilient mandibular
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resilient mandibular bar-retained overdenture on two implants
Trial: 9080749
Drug: Implants in
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants in the maxilla splinted by a rigidly cast bar
Trial: 9080749
Drug: Overdenture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overdenture therapy
Trial: 7118065
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg p.o.)
Trial: 2439821
Drug: Bopindolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol (1 mg p.o.)
Trial: 24394187
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B virus (HBV) envelope DNA vaccine
Trial: 21628602
Drug: NAP/ESO tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAP/ESO tablet (500 mg EC naproxen + 20 mg non-EC esomeprazole magnesium)
Trial: 21628602
Drug: EC naproxen
RxNorm normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC naproxen tablet alone
Trial: 21628602
Drug: EC esomeprazole
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EC esomeprazole magnesium capsule alone
Trial: 21628602
Drug: EC naproxen
RxNorm normalized name: Naproxen 375 MG Oral Tablet, Enteric Coated [EC NAPROXEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC naproxen tablet + EC esomeprazole magnesium capsule
Trial: 20032480
Drug: Maternal nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal nutritional status and supplement intake
Trial: 18721511
Drug: Moderate statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate statin therapy
Trial: 18222355
Drug: Intensive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive and moderate statin therapy
Trial: 15009510
Drug: Single melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single melatonin pill (5 mg)
Trial: 15009510
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of light pulse and melatonin
Trial: 11587165
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day of oral amlodipine
Trial: 11587165
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amlodipine (baseline) + 5 mg of amlodipine (additional)
Trial: 11587165
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amlodipine (baseline) + 25 mg of hydrochlorothiazide (HCTZ)
Trial: 11587165
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amlodipine (baseline) + 20 mg of benazepril
Trial: 7988255
Drug: Functional Living
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Living Index‐Cancer (FLIC) administered to patients
Trial: 7988255
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of chemotherapy
Trial: 3108159
Drug: Carbohydrate in
RxNorm normalized name: Soy-based no added carbohydrate infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate in combination with fat emulsions (fat group)
Trial: 3108159
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate solutions (carbohydrate group)
Trial: 26047766
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs (0.315 g per capsule, 3 capsules daily)
Trial: 22262230
Drug: N-acetylcysteine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg every 12 hours for 4 days
Trial: 22262230
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg every 24 hours for 4 days
Trial: 20522656
Drug: Comprehensive specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive specific care plan with standardised twice yearly consultation
Trial: 16929239
Drug: Arginine-enhanced formula
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine-enhanced formula (17 g/day)
Trial: 16138795
Drug: Home care
RxNorm normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home care treatment delivered by primary care teams
Trial: 16138795
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment as usual
Trial: 11856154
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy plus six cycles of chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) followed by tamoxifen 20 mg daily for 5 years
Trial: 11856154
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (historical control population who never received systemic therapy)
Trial: 11856154
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with positive and negative hormone receptor status
Trial: 7869147
Drug: Oral instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral instructions by certified nurse-midwife in addition to written instructions (Group 2, n = 45)
Trial: 2673079
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily dose of hydroxychloroquine sulphate
Trial: 2673079
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg daily dose of hydroxychloroquine sulphate
Trial: 347232
Drug: Full-cream milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-cream milk powder (control)
Trial: 25966679
Drug: Periarticular infiltrations
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular infiltrations and continuous post-operative intra-articular infusion of local anaesthetics (PIAC group)
Trial: 25037695
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with potential up-titration to 150 mg Q2W at week 12 if LDL-C was ≥ 70 mg/dL at week 8.
Trial: 25037695
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day.